News & Updates
Showing Pharmacy articles
Showing
SHASTA trials boost plozasiran potential in severe hypertriglyceridaemia
In the SHASTA-3 and SHASTA-4 trials, quarterly administration of plozasiran reduced triglyceride (TG) levels and acute pancreatitis (AP) events in individuals with severe hypertriglyceridaemia (sHTG; TG ≥500 mg/dL).
Tailored therapy reduces antibiotic use in infective endocarditis
A response-tailored strategy decreases antibiotic duration by 2 weeks compared with standard therapy in patients with left-sided infective endocarditis, without compromising their safety. This is the primary result of the POET-II study presented at ESC Congress 2026.
Add-on tafasitamab–lenalidomide improves PFS in BCLs
In the global phase III frontMIND study, adding tafasitamab and lenalidomide (Tafa-Len) to an R-CHOP* chemotherapy regimen significantly improves progression-free survival in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade BCL (HGBCL).
Tebentafusp delivers 5-year survival benefit in metastatic uveal melanoma
Long-term survival benefits with tebentafusp persist in previously untreated HLA-A∗02:01-positive patients with unresectable or metastatic uveal melanoma (mUM), as shown in the longest survival follow-up of a phase III trial.
Lorlatinib delivers long-term survival benefits in advanced ALK-positive NSCLC
First-line treatment with lorlatinib demonstrates long-term survival benefits in patients with advanced anaplastic lymphoma kinase (ALK)-positive nonsmall cell lung cancer (NSCLC), as shown in the 7-year update from the phase III CROWN study.
Real-world study supports new therapeutics for BRAF-mutant metastatic CRC
A real-world study presented at ESMO GI 2026 shows that pembrolizumab immunotherapy and a combination regimen of encorafenib and cetuximab are associated with meaningful survival benefits in BRAF-mutant metastatic colorectal cancer (CRC).